· Regulation · Regulation Desk
Neither injectable semaglutide nor tirzepatide currently appears on the FDA active shortage list, removing the 503A/503B exemption compounders relied on. The legal foundation for the ongoing crackdown on compounded GLP-1s, explained.
This brief is part of the Novusyn Research news desk. We track peptide clinical readouts, regulatory actions, and pharma developments in neutral, evidence-led language for scientifically literate readers.
For related context, see the full news desk, clinical trials tracker, regulation tracker, compound directory, and guides library.